Lyudmila V. Shogenova

Lyudmila V. Shogenova

Auto-generated profile, based on publicly available information

Lyudmila V. Shogenova

Federal State Autonomous Educational Institution of Higher Education “N.I.Pirogov Russian National Research Medical University” of the Ministry of Health of the Russian Federation

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 December 2020 in Annals of the Russian academy of medical sciences
Verified
Journal Article
Open access
PDF file
LSLyudmila V. Shogenova
Lyudmila V. Shogenova
SPSergey S. Petrikov
Sergey S. Petrikov
SZSergey Vladimirovich Zhuravel
Sergey Vladimirovich Zhuravel
PGPavel V. Gavrilov
Pavel V. Gavrilov
IUIrina I. Utkina
Irina I. Utkina
ACAlexander Chuchalin
Alexander Chuchalin
Background. The paper discusses the use of a thermal helium-oxygen mixture (t-Не/О2 ), a novel technology, in treating patients with the 2019-nCoV acute respiratory disease (COVID-19) who develop life-threatening respiratory failure. Aim to evaluate the safety and efficacy of t-Не/О2 inhalation combined with standard therapy in the treatment of acute respiratory failure in patients with COVID-19. Materials and Methods. This was a single-center, randomized, prospective study of 70 patients with COVID-19. All patients were divided into two groups: in Group 1 (n = 38) patients received t-He/О2 in addition to the standard COVID-19 treatment; and in Group 2 (n = 32) patients were given the standard treatment in accordance with the Clinical Treatment Guidelines for patients with COVID-19, developed by the Ministry of Health of the Russian Federation. The male/female ratio was 18/20 in Group 1 and 18/14 in Group 2. The mean age of the patients in the study was 53.5 years (43; 62): 56 years (42; 64) in Group 1 and 52 years (43; 66) in Group 2. All patients had computed tomography (CT) signs of lung injury: ground-glass opacities and areas of consolidation. SARS-CoV-2 RNA was detected in 30 Group 1 patients and 28 Group 2 patients. The patients were matched by sex, age, body mass index (BMI), area of pulmonary involvement, and laboratory findings. All patients provided voluntary informed consent to participate in the study and signed a consent form. Results. Inhalation of thermal helium-oxygen mixture combined with standard therapy did not cause any procedure-related side effects in any of the patients. The following changes were observed in all patients: pO2 /FiO2 , SpO2 , and lymphocyte counts increased, C-reactive protein (CRP) levels decreased, and D-dimer and ferritin levels returned to normal. In Group 1 statistically significant changes in the above-mentioned parameters were seen within three days, while in Group 2 the same changes were observed between Days 7 and 10 of treatment. In Group 1 patients cleared SARS-CoV-2 within 4872 hours after initiation of inhalation, which was confirmed by polymerase chain reaction (PCR), and in Group 2 virus elimination was achieved within 72168 hours. Conclusion. The addition of inhalation of a thermal gas mixture of helium and oxygen (t-He/О2 ) to the standard therapy for patients with SARS-CoV-2 infection, CT signs of pneumonia (grades СT2 or CT3), and acute respiratory failure improves gas exchange, contributes to a more rapid virus elimination, and indirectly reduces inflammation.

26 October 2020 in PULMONOLOGIYA
Verified
Journal Article
Open access
PDF file
LSL. V. Shogenova
L. V. Shogenova
SVS. D. Varfolomeev
S. D. Varfolomeev
VBV. I. Bykov
V. I. Bykov
STS. B. Tsybenova
S. B. Tsybenova
ARAnna Ryabokon
Anna Ryabokon
APA. A. Panin
A. A. Panin
Влияние термической гелий-кислородной смеси на вирусную нагрузку при COVID-19

30 April 2022 in PULMONOLOGIYA
Verified
Journal Article
Closed access
PDF file
TSTuyet Thi Struong
Tuyet Thi Struong
LSL. V. Shogenova
L. V. Shogenova
VSV. D. Selemir
V. D. Selemir
ACAlexander Chuchalin
Alexander Chuchalin
Therapy with inhaled nitric oxide (iNO) in patients with hypercapnic respiratory failure (RF) and pulmonary arterial hypertension (PAH) is currently of scientific interest. The aim of this study was to evaluate the effects of iNO therapy on COPD patients with hypercapnic RF and PAH during exacerbation of the disease.Methods. A randomized, prospective, controlled trial included 30 patients with COPD (age 65 (62; 75) years) with hypercapnic RF and pulmonary arterial hypertension (PAH) treated at the State Budgetary City Teaching Hospital “City Clinical Hospital named after D.D.Pletnev of Healthcare Moscow City Department” (2021). The inclusion criteria were: PaCO2 ≥ 45 mm Hg and pulmonary artery systolic pressure PASP > 40 mm Hg as accessed by Doppler echocardiography. The patients were divided into two groups. Patients of the main group were administered iNO in the form of daily 90-minute sessons for two weeks using Tianoks device (Russian Federal Nuclear Center – All-Russian Research Institute of Experimental Physics, State Corporation “Rosatom”, Russia). Patients of the control group received treatment that corresponded to the severity of their COPD exacerbation according to the guidelines by Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2020 – 2021. Hemodynamics and gas exchange, exercise tolerance, vascular stiffness, and obstructive disorders were assessed at baseline, on Days 7 and 14.Results. The main group demonstrated a decrease in PASP (38 (32; 43) mm Hg vs 47 (44; 54) mm Hg; p = 0.001), a decrease in stiffness index (SI) (7.03 m / s (5.3; 19.2) vs 12.2 m / s (5.7; 15.1); p = 0.01), decrease the pulmonary shunt fraction (Qs / Qt) (4.33% (3.7; 6.1) vs 9.12% (7.12; 11.3); p = 0.01), an increase in arterial vascular tone measured by reflective index (RI) (62.4% (51.2; 64.3) vs 58.5% (51.7; 63.8); p = 0.01), and increased exercise tolerance measured by 6-minute walking test (6MWT) (358.1 m (320.5; 368.2) vs 321.5 m (280.4; 329.1); p = 0.001) as compared to the control group.Conclusion. Our study indicates that iNO-therapy effectively reduces hypoxemia, endothelial dysfunction, improves hemodynamics, walking distance, and exercise tolerance during the exacerbation of COPD in patients with hypercapnic RF and PAH.

15 April 2025 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
LSLudmila V. Shogenova
Ludmila V. Shogenova
ШВШогенова Людмила Владимировна
Шогенова Людмила Владимировна
Aim. To study the efficacy and safety of the combined use of thermal heliox (t-He/O2), nitric oxide (NO) and molecular hydrogen (H2) in patients with exacerbation of chronic obstructive pulmonary disease (COPD) complicated by hypoxemic, hypercapnic respiratory failure (RF) and secondary pulmonary arterial hypertension (PAH) in the post-COVID period. Materials and methods. The randomized, comparative, controlled, parallel study included patients (n=100, 52 men and 48 women) with exacerbation of COPD levels of evidence C and D (GOLD 2021–2023) with hypoxemic, hypercapnic respiratory failure and secondary PAH, who had pneumonia caused by SARS-CoV-2 before hospitalization. Patients with similar demographic, clinical, and functional parameters, who received non-invasive ventilation (NIV) and oxygen (O2) along with standard drug therapy, were divided into 5 groups: Group 1 (main): (n=22: 12 men, 10 women, who received t-He/O2, NO, and H2 sequentially); Group 2 (n=20: 10 men, 10 women, who received t-He/O2 and NO); Group 3 (n=20: 11 men, 9 women, who received t-He/O2 and H2); Group 4 (n=18: 10 men, 8 women, who received NO and H2); Group 5 (control) (n=20: 9 men, 11 women). The dynamics of the clinical condition of patients, gas exchange in the lungs, acid-base balance, left-to-right discharge fraction, hemodynamic parameters, and exercise tolerance were assessed. Results. A positive effect of the complex use of medical gases on the clinical condition of patients, gas exchange parameters in the lungs, metabolism, hemodynamic parameters and exercise tolerance was found in comparison with these parameters in patients who received medical gases separately and with the control group. Conclusion. The combination of t-He/O2, NO and H2 with simultaneous pathogenetic therapy and NIV in patients with exacerbation of COPD complicated by hypoxemic, hypercapnic RF and secondary PAH in the post-COVID period is safe and more effective compared to groups receiving each medical gas separately. Complex therapy improves the clinical condition of patients, reduces signs of hypoxemia and hypercapnia, vascular endothelial dysfunction, metabolic disorders and increases tolerance to physical activity by normalizing gas exchange in the lungs, increasing oxygen delivery to tissues, reducing the shunt fraction, and restoring metabolism.

10 April 2023 in Cardiovascular Therapy and Prevention
Verified
Journal Article
Open access
PDF file
ARAnna Ryabokon
Anna Ryabokon
NZNatalia V Zakharova
Natalia V Zakharova
MIM. I. Indeikina
M. I. Indeikina
Alexey S. KononikhinAlexey S. Kononikhin
Alexey S. Kononikhin
LSL. V. Shogenova
L. V. Shogenova
ACAlexander Chuchalin
Alexander Chuchalin
Aim. To study the effect of inhalation therapy with an active hydrogen (AH) on the protein composition of exhaled breath condensate (EBC) in patients with post-COVID syndrome (PCS).Material and methods. This randomized controlled parallel prospective study included 60 patients after coronavirus disease 2019 (COVID-19) with PCS during the recovery period and clinical manifestations of chronic fatigue syndrome who received standard therapy according to the protocol for managing patients with chronic fatigue syndrome (CFS). The patients were divided into 2 groups: group 1 (main) — 30 people who received standard therapy and AH inhalations (SUISONIA, Japan) for 10 days, and group 2 (control) — 30 medical workers who received only standard therapy. Patients in both groups were comparable in sex and mean age. All participants in the study were sampled with EBC on days 1 and 10. Samples were subjected to tryptic digestion and high-performance liquid chromatography combined with tandem mass spectrometry analysis using a nanoflow chromatograph (Dionex 3000) in tandem with a high-resolution time-of-flight mass spectrometer (timsTOF Pro).Results. A total of 478 proteins and 1350 peptides were identified using high resolution mass spectrometry. The number of proteins in samples after AH therapy, on average, is 12% more than before treatment. An analysis of the distribution of proteins in different groups of patients showed that only half of these proteins (112) are common for all groups of samples and are detected in EBC before, after, and regardless of hydrogen therapy. In addition to the qualitative difference in the EBC protein compositions in different groups, quantitative changes in the concentration of 36 proteins (mainly structural and protective) were also revealed, which together made it possible to reliably distinguish between subgroups before and after treatment. It is worth noting that among these proteins there are participants of blood coagulation (а-1-antitrypsin), chemokine- and cytokine-mediated inflammation, and a number of signaling pathways (cytoplasmic actin 2), response to oxidative stress (thioredoxin), glycolysis (glyceraldehyde-3- phosphate dehydrogenase), etc.Conclusion. The use of hydrogen therapy can contribute to the switching of a number of physiological processes, which may affect the success of recovery in PCS patients. In particular, the obtained results indicate the activation of aerobic synthesis of adenosine triphosphate in mitochondria by hydrogen therapy, which correlates well with the decrease in the blood lactate level detected by laboratory studies. At the same time, this therapy can inhibit pro-inflammatory activity, negatively affecting the coagulation and signaling pathways of integrins and apoptosis, and, in addition, activate protective pathways, tricarboxylic acid cycle, FAS signaling, and purine metabolism, which may be essential for effective recovery after COVID-19.

15 March 2022 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
OSOksana Svitich
Oksana Svitich
IBIrina Baranova
Irina Baranova
NKNadezhda O. Kryukova
Nadezhda O. Kryukova
APAlexander Poddubikov
Alexander Poddubikov
AVAlexandra B. Vinnitskaya
Alexandra B. Vinnitskaya
ЗВЗахарова Валерия Владимировна
Захарова Валерия Владимировна
Aim. To study the inhalation of an active form of hydrogen effect to mucosal and system immunity in a rehabilitation program for health workers. Materials and methods. The study involved patients that survived COVID-19 after therapy with inhaled hydrogen for 90 minutes (n=30), and a control group of patients treated according to standard protocol for managing patients that survived COVID-19 during the rehabilitation period (n=30). Biomaterial was carried out in 2 stages: on the first day of the study, before the accepted therapy and on the 10th day of the study. The indicators of humoral and cellular immunity were studied. The levels of secretory immunoglobulin A (sIgA) and IgG were investigated using the method of enzyme-linked immunosorbent assay. Phagocytosis was assessed on a Beckman Coulter FC-500 flow cytometer. Statistical data processing was carried out in the GraphPad Prism 7.00 software using nonparametric methods. Results. It was shown that the phagocytic index (PI) of monocytes in nasal scrapings after inhaled hydrogen treatment did not significantly change relative to the first day of treatment and control, while the PI of granulocytes in nasal scrapings significantly increased relative to the first day by 2.5 times (p=0.000189), as well as relative to the control by 1.1 times (p=0.047410). PI of monocytes in pharyngeal scrapings showed a significant increase relative to the first day of treatment by 2.8 times (p=0.041103), however, did not differ relative to the control. PI of granulocytes of pharyngeal scraping did not differ significantly relative to the first day and control. PI of granulocytes and blood monocytes of the studied group did not change significantly. PI of granulocytes and monocytes of peripheral blood relative to control during therapy did not change. The sIgA level in nasal scrapings significantly increased by 2.9 times, while in pharyngeal scrapings the level of sIgA significantly decreased by 2 times. Сonclusion. We have shown an increase in granulocytes PI in the nasal cavity and oral monocytes, as well as in the level of sIgA in the nasal cavity during therapy with active hydrogen. The data obtained indicate the effectiveness of therapy, which can be used both in the treatment of COVID-19, and in post-COVID syndrome as an additional therapy. The absence of changes in blood parameters, as well as individual links in nasal and pharyngeal scrapings, requires further study to develop ways to overcome treatment tolerance.